While serum prostate specific antigen (PSA) testing improved early detection of prostate tumors, implementation of this tool also created a large patient population in which identified cancer lesions were actually indolent. For patients who choose to undergo prostatectomy, cancer aggressiveness can only be determined by post-procedure pathology analysis of cancerous tissue. Additionally, cancer recurrence predictions are often unreliable. As an alternative method to aid decisions regarding treatment, we sought to develop MRS tools which can predict cancer aggressiveness based on the novel use of histologically benign (Hb) tissue.
This abstract and the presentation materials are available to members only; a login is required.